Back to Search
Start Over
Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older.
- Source :
-
Vaccine [Vaccine] 2016 Jun 24; Vol. 34 (30), pp. 3454-62. Date of Electronic Publication: 2016 May 05. - Publication Year :
- 2016
-
Abstract
- Background: Vaccination effectively reduces invasive disease and pneumonia caused by Streptococcus pneumoniae. However, waning antibody titers and the ability of revaccination to boost titers in older adults have been concerns. A study to describe antibody persistence after vaccination with 13-valent pneumococcal conjugate vaccine (PCV13) and response to revaccination 5 years after the initial dose was conducted.<br />Methods: Pneumococcal vaccine-naive subjects aged 50-59 years were randomized and vaccinated with PCV13 plus trivalent inactivated influenza vaccine concomitantly or 1 month apart, then revaccinated with PCV13 five years later. Antipneumococcal polysaccharide opsonophagocytic activity (OPA) geometric mean titers (GMTs) and immunoglobulin G (IgG) geometric mean concentrations (GMCs) were determined before and approximately 1 month after each vaccination. Targeted local reactions and systemic events were collected for 14 days, adverse events (AEs) for 1 month, and serious AEs (SAEs) for 6 months after each vaccination.<br />Results: Of 1116 randomized subjects, 727 were revaccinated at year 5. Between the time of initial vaccination and revaccination, OPA GMTs and IgG GMCs declined but remained higher than levels before initial vaccination for 12 of the 13 vaccine serotypes. One month after revaccination, OPA GMTs and IgG GMCs were comparable with, or higher than, levels observed 1 month after initial vaccination for most vaccine serotypes. Local reactions were mostly mild. AEs were reported by <5% and SAEs by <1% of subjects at 1 and 6 months after revaccination, respectively. No SAEs were vaccine-related.<br />Conclusions: Revaccination of adults ≥50 years with PCV13 five years after primary vaccination was safe and immunogenic. Additionally, antibody titers were maintained for at least 5 years after vaccination. The vaccine stimulated a memory response as shown by enhanced responses that were maintained or enhanced by revaccination. CLINICALTRIALS.<br />Gov Registration: NCT00521586.<br /> (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Subjects :
- Antibodies, Bacterial blood
Cross-Over Studies
Double-Blind Method
Female
Humans
Immunoglobulin G blood
Immunologic Memory
Influenza Vaccines administration & dosage
Male
Middle Aged
Pneumococcal Infections prevention & control
Pneumococcal Vaccines therapeutic use
Immunization, Secondary
Immunogenicity, Vaccine
Pneumococcal Vaccines administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 1873-2518
- Volume :
- 34
- Issue :
- 30
- Database :
- MEDLINE
- Journal :
- Vaccine
- Publication Type :
- Academic Journal
- Accession number :
- 27155493
- Full Text :
- https://doi.org/10.1016/j.vaccine.2016.04.093